在心力衰竭患者中,CRT反应和患者退出得分之间的相关性与减少射出分数的心力衰竭患者
Aritra Paul1, Joe Demian1, Niraj Varma1
1Cardiac Electrophysiology and Pacing Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Journal of cardiovascular electrophysiology
|August 6, 2025
概括
经过心脏再同步治疗 (CRT) 的心力衰竭患者通常不会后悔手术,无论CRT反应如何. 设备植入的满意度仍然很高,无论心声回声图的改进.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 患者的治疗结果.
背景情况:
- 心脏再同步治疗 (CRT) 的有效性与患者满意度之间的关系尚不清楚.
- 评估患者对CRT的看法对于了解治疗的整体影响至关重要.
研究的目的:
- 通过使用决策遗憾量表 (DRS) 调查CRT反应和患者报告的结果之间的相关性.
- 为了评估CRT植入心力衰竭后的患者满意度,心力衰竭患者减少喷射率 (HFrEF).
主要方法:
- 150名接受CRT植入的HFrEF患者在术后6个月使用DRS进行了评估.
- 通过心声回应测定了CRT反应 (LVEF改善>5%,LVESV减少>10%).
- 患者在完成DRS时不知道他们的CRT响应状态.
主要成果:
- 没有患者报告对CRT设备植入有重大遗憾.
- 在CRT响应者和非响应者之间没有观察到DRS得分的统计学上显著差异.
- 响应者 (43%) 的平均LVEF显著高于非响应者 (27%) (p<0.001).
结论:
- 接受CRT的HFrEF患者报告了他们决定的压倒性积极感,无论CRT反应如何.
- 显著的心脏改造或CRT反应没有影响患者对接受CRT植入的决定的满意度.
相关概念视频
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure IV: Classification and Diagnostic Evaluation
33
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
33
Heart Failure III: Clinical Manifestations
47
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
47
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Mitral Regurgitation IV: Nursing Management
83
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
83
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509


